Get started
Solid Biosciences Inc.Solid Biosciences Inc.Solid Biosciences Inc.

Solid Biosciences Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

SLDB trade ideas

SLDB: S-1 Support Broken, Eyes on S-2 The stock has now broken below S-1 support at $2.92, confirmed by a large red candle signaling a clear downside breakout. With small-cap biotech under heavy pressure, a move toward S-2 support at $1.84 (dating back to Oct. 2023) is now a real possibility. Not trying to pick on the stock — just calling what’s in front of us. I’ve held off buying so far, and looking back, that patience is paying off. Still watching for a better entry. Stay tuned.
NASDAQ:SLDB
by BluntForceOptions
SLDB: My downside targets remain:After falling below the lower trendline of its pennant formation, SLDB remains under pressure, with technicals pointing to further downside. S1: $4.48 – First support level, potential reaction area. S2: $4.03 – Offering price and key support zone. With bearish price action and technicals in play, a move toward S1 looks increasingly likely. If that level doesn’t hold, S2 becomes the next downside target. Patience remains key. New chart, same setup—key levels remain in focus. 🚨
NASDAQ:SLDB
by BluntForceOptions
SLDB/USD – 30-Min Long Trade Setup!📌 🚀 🔹 Asset: SLDB (Solid Biosciences Inc.) 🔹 Timeframe: 30-Min Chart 🔹 Setup Type: Bullish Breakout Trade 📌 Trade Plan (Long Position) ✅ Entry Zone: Above $5.58 (Breakout Confirmation) ✅ Stop-Loss (SL): Below $5.29 (Support Breakdown) 🎯 Take Profit Targets: 📌 TP1: $5.90 (First Resistance Level) 📌 TP2: $6.33 (Extended Bullish Move) 📊 Risk-Reward Ratio Calculation 📈 Risk (SL Distance): $5.58 - $5.29 = $0.29 risk per share 📈 Reward to TP1: $5.90 - $5.58 = $0.32 (1:1.1 R/R) 📈 Reward to TP2: $6.33 - $5.58 = $0.75 (1:2.6 R/R) 🔍 Technical Analysis & Strategy 📌 Descending Triangle Breakout: Price is breaking out of a descending trendline, signaling a bullish reversal. 📌 Bullish Momentum Building: A breakout above $5.58 with strong volume will confirm the move. 📌 Volume Confirmation Needed: Ensure high volume when price breaks resistance to confirm bullish momentum. 📌 Momentum Shift Expected: If the price stays above $5.58, a move toward $5.90 and then $6.33 is likely. 📊 Key Support & Resistance Levels 🟢 $5.29 – Strong Support / Stop-Loss Level 🟡 $5.58 – Entry / Breakout Level 🔴 $5.90 – First Resistance / TP1 🟢 $6.33 – Final Target / TP2 📉 Trade Execution & Risk Management 📊 Volume Confirmation: Ensure strong buying volume above $5.58 before entering. 📈 Trailing Stop Strategy: Move SL to entry ($5.58) after TP1 ($5.90) is hit. 💰 Partial Profit Booking Strategy: ✔ Take 50% profits at $5.90, let the rest run toward $6.33. ✔ Adjust Stop-Loss to Break-even ($5.58) after TP1 is reached. ⚠️ Fake Breakout Risk ❌ If the price fails to hold above $5.58 and drops back, exit early to avoid losses. ❌ Wait for a strong bullish candle close above $5.58 before entering aggressively. 🚀 Final Thoughts ✔ Bullish Setup – Breaking above $5.58 could lead to higher targets. ✔ Momentum Shift Possible – Watch for volume confirmation. ✔ Favorable Risk-Reward Ratio – 1:1.1 to TP1, 1:2.6 to TP2. 💡 Stick to the plan, manage risk, and trade smart! 🚀🏆 🔗 #StockTrading #SLDB #BreakoutTrade #TechnicalAnalysis #MomentumStocks #ProfittoPath #TradingView #StockMarket #SwingTrading #RiskManagement #ChartAnalysis 📈🔥
NASDAQ:SLDBLong
by ProfittoPath
SOLID BIOSCIENCES—$SLDB CASHES UP FOR GENE THERAPY PUSHSOLID BIOSCIENCES— NASDAQ:SLDB CASHES UP FOR GENE THERAPY PUSH (1/9) Good afternoon, Tradingview! Solid Biosciences is stacking cash—no revenue yet, but a $200M raise has tongues wagging 📈🔥. NASDAQ:SLDB ’s betting big on gene therapy—here’s the scoop! 🚀 (2/9) – CASH, NOT SALES • Revenue: Zilch—clinical-stage vibes 💥 • Q3 ‘24 Loss: $0.61/share, missed $0.58 est. 📊 • Cash Boost: $200M offering just landed No sales, but NASDAQ:SLDB ’s war chest is growing! (3/9) – BIG MOVE • Feb 18 Raise: $200M via 35.7M shares, warrants 🌍 • Cash Pile: Was $171M, now nearing $350M 🚗 • Goal: Fuel SGT-003 trials into ‘27 🌟 NASDAQ:SLDB ’s loading up for the long haul! (4/9) – SECTOR CHECK • Market Cap: $500M post-raise 📈 • Vs. Peers: Sarepta’s 13B dwarfs it—revenue rules • Edge: Low EV ($150M), big therapy dreams Undervalued biotech bet or long shot? 🌍 (5/9) – RISKS ON DECK • Trials: SGT-003 flops could sink it ⚠️ • Sentiment: 30% drop from Jan peak—jitters 🏛️ • Burn: $20-25M/quarter—clock’s ticking 📉 High stakes, high risks—can it deliver? (6/9) – SWOT: STRENGTHS • Cash: $200M raise powers trials 🌟 • SGT-003: Early data dazzles, Fast Track nod 🔍 • DMD Focus: Huge need, blockbuster shot 🚦 NASDAQ:SLDB ’s got fuel and firepower! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: No revenue, all-in on one play 💸 • Opportunities: $2-4B cap if trials pop 🌍 Can NASDAQ:SLDB turn cash into a cure? (8/9) – NASDAQ:SLDB ’s $200M haul—your take? 1️⃣ Bullish—Gene therapy gold ahead. 2️⃣ Neutral—Wait for trial proof. 3️⃣ Bearish—Risks outweigh the buzz. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:SLDB ’s revenue-free, but $200M keeps SGT-003 alive—stock’s buzzing 🌍🪙. Low EV vs. peers, yet trials and rivals loom. Cure or bust?
NASDAQ:SLDBLong
by DCAChampion
SLDB — Key levels to watch: Today's positive trial data pushed Solid Bioscience's stock above $7 before the offering news weighed on upside momentum. Despite this, I have my eye on a key multi-month trendline that suggests potential support around $4.48, which remains 11.17% above the offering price of $4.03. This level aligns with prior trendline resistance on the downtrend, now potentially flipping to support. With strong initial trial results still in play, I’ll pull the trigger around $4.48 if it holds. After more than three decades of trading, much of it focused on the biotech sector, I’ve learned that chasing these scenarios rarely ends well—patience always pays. IMHO, for those without a position, sitting on your hands and waiting for confirmation at support is likely the smarter move. Chart tells the story—watch this level closely. Good luck to everyone. 📉📈
NASDAQ:SLDB
by BluntForceOptions
RiskMastery's Breakout Stocks - SLDB EditionWelcome to RiskMastery's Breakout Stocks - Stocks with breakout potential. In this edition, we'll be looking at NASDAQ:SLDB ... I believe this code is at a point of potential volatility. If price can hold above $6.77 ... Bullish potential may be unlocked. My key upside targets include: - $8.41 (Conservative) - $10.80 (Medium) - $13.53 (Aggressive) If however price falls below $4.17 ... Bearish risk potential may be unlocked. (My key risk targets - C, M,& A - are as noted on the chart) Enjoy, and I look forward to being of further service into the future. If you'd like to connect, feel free to reach out and comment below. Mr RM | Risk Mastery Disclaimer: This post is intended for educational purposes only - Publicly available RiskMastery information & content is not intended to be financial advice in any shape or form. Please do your own research and seek advice from a licensed professional before acting on any of the information contained within this post. This post is not a solicitation or recommendation to buy, sell or hold any positions in any financial instrument. All demonstrated trades are merely incidental to the educational training RiskMastery aims to provide. You are solely responsible for your own investment and trading decisions, of which should be made only according to your own opinion, knowledge and experience. You should not rely on any of the information contained on this site or contained in any RiskMastery material on any website or platform. You assume the sole risk of any trade or investment you elect to make. RiskMastery and affiliates shall not be liable to you for any monetary losses or any other damages incurred directly or indirectly, from your use, reliance or reference of RiskMastery materials, content and educational information. Thank you for your understanding and cooperation - We look forward to working with you into the future to navigate the fine line of trading and investment success.
NASDAQ:SLDBLong
by Bullfinder-official
SLDB tARGET $7.00TECHNICAL ANALYSIS EN//// Price closed a GAP of 20% on June 21. We see a clear trend change, price is now above the MA 20 & 50, looking for bounces in the MA50 and Ichimoku Clouds. On March 21 it made a GAP DOWN of -14%, which the price should close. Total Debt: 4.6 M Vs Total Assets 285.2 M Total insider Buys/Sells last 6 months: Buys $27,688,435 Sells $546,854 ES//// Precio cerró un GAP de 20% del 21 de Junio. .Vemos un claro cambio de tendencia, el precio ahora está por encima de las MA 20 & 50, buscando rebotes en la MA50 y en Nubes de Ichimoku. El 21 de Marzo hizo un GAP DOWN de -14%, que el precio debería cerrar. Deuda total: 4.6 M Vs Activos Totales 285.2 M Total de compras / ventas internas de los últimos 6 meses: Buys $27,688,435 Sells $546,854 🟢$SLDB SL $3.30 TP1 $6.50 FEAR & GREED INDEX : 52 -Neutral “sea temerosos cuando otros son codiciosos, y sólo codicioso cuando otros son temerosos” “be fearful when others are greedy, and only greedy when others are fearful” - Warren Buffett PRICE TARGET: $7.00 X Jefferies $8.0 x Barclays $8.00 x Credit Suisse HEDGE FUND TRACK: New Positions: 40 Increased Positions:32 Total Calls : 838.288 Thousand prior 538 Thousnad Important note: ⚠️ All trades have risks that the investor must consider before investing. VivirdelTrading.club makes a disclaimer of any operation that may generate losses. All information transmitted by the channel, the page and the alert system is shared in good faith. There is no guarantee of 100% of the executed operations, as these are based on statistical models and assumptions regarding the past behavior of the price of a share, but they do not guarantee the same future behavior.
NASDAQ:SLDBLong
by Vivir_Del_Trading
$SLDB FDA Lifts Clinical Hold case studySolid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Phase I/II Clinical Trial As announced in July 2020, the FDA had requested further manufacturing information, updated safety and efficacy data for all patients dosed, and provided direction on total viral load to be administered per patient. Based on the Company’s response to these requests, the FDA acknowledged that the Company satisfactorily addressed all clinical hold questions. “We are working diligently to complete all activities necessary to resume dosing, which we expect to occur in the first quarter of 2021.” finance.yahoo.com
NASDAQ:SLDB
by AlenCiken
Solid Biosciences Announces $90 Million Private PlacementSolid Biosciences Announces $90 Million Private Placement Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions. The private placement includes new investors Suvretta Capital Management, LLC and Aspire Capital Fund, LLC and existing investors, including RA Capital Management, Perceptive Advisors, LLC, Bain Capital Life Sciences, EcoR1 Capital, LLC, Boxer Capital, and Ikarian Capital, LLC, as well as certain board members and executive officers. In this private placement, the Company is selling 24,324,320 shares of common stock at a price of $3.70 per share. The Company expects to use net proceeds from the private placement to fund research and development expenses, including the advancement of SGT-001, and for working capital and other general corporate purposes. finance.yahoo.com
NASDAQ:SLDB
by AlenCiken
#VolatilityWatch Solid BioscencesBiotech buyouts have been very strong, especially with Gene therapy stocks as of late. Bounced off Lower end of channel Gartley pattern bounced off 1.618 fib extension along with important reversal leg of Elliott Wave Theory. if price holds inside the lower end of the channel there is a potential move back up and test the gap. looking for nice $0.40+ swing from current level. Disclosure: I am long SLDB. I may buy/ sell within the next 72 hours. I am not a financial adviser. Please do your homework before investing.
NASDAQ:SLDBLong
by follow_the_money